In Ewing's sarcomas, chromosomal translocations cause the N-terminal domain of the EWS (Ewing's sarcoma protein) to fuse with the DNA-binding domains of the Ets (E26 transformationspecific) family of transcription factors. Here we show that EWS and EWS-Fli1 (Friend leukaemia virus integration 1), the fusion most frequently found in Ewing's sarcomas, become phosphorylated at Thr 79 in response to either mitogens or DNA-damaging agents. The much weaker mitogen-induced phosphorylation of EWS is catalysed by the MAPKs (mitogen-activated protein kinases) ERK1 (extracellular signal-regulated kinase 1) and ERK2, whereas the much stronger phosphorylation of EWS induced by the DNA alkylating agent MMS (methyl methanesulphonate) can be catalysed by JNK (c-Jun N-terminal kinase) and at least one other protein kinase distinct from ERK1/ERK2. In contrast, the phosphorylation of EWS-Fli1 induced by MMS was largely mediated by p38α/p38β MAPKs. MMS induced a much stronger phosphorylation of EWS-Fli1 than EWS in heterodimers comprising both proteins.
INTRODUCTION
The EWS (Ewing's sarcoma protein) is one of the three human members of the TET family of putative RNA-binding proteins, together with TLS/Fus and TAFII68 [1] . The central part of EWS features a nucleic acid recognition motif, and the Cterminus contains three arginine-glycine-glycine-rich regions that are believed to be required for RNA binding [2] . On the other hand, the N-terminal region is serine-tyrosine-glutamine-glycinerich and can potently stimulate gene transcription if fused with a heterologous DNA-binding domain [3] . Male and female EWS null animals are sterile, indicating a role in meiosis [4] . Furthermore, zebrafish in which both EWS gene orthologues are not expressed displayed mitotic defects and enhanced apoptosis, and similar effects were observed in human HeLa (cervical carcinoma) cells upon siRNA (small interfering RNA) silencing of EWS [5] . However, molecular actions of EWS are not understood. Based on reports of interaction with various splicing factors and components of the basal transcriptional machinery, EWS has been implicated both in transcription and RNA splicing, acting like a basal transcription factor or even an adapter protein between transcription and pre-mRNA splicing [3, [6] [7] [8] .
Ewing's sarcoma is an aggressive and frequently metastatic tumour that primarily affects children and young adults. It arises primarily in bone, but in approx. 15 % of Ewing's sarcoma patients the primary site of the tumour is within the soft tissue [9] [10] [11] . Ewing's sarcoma is characterized by a chromosomal translocation that fuses the 5 end of the EWS gene with the 3 end of one of the genes of the Ets (E26 transformation-specific) family of transcription factors [12] . As a result, fusion proteins composed of the N-terminal transactivation domain of EWS and the C-terminal DNA-binding domain of an Ets protein are generated in cells [13, 14] . The most common fusion in Ewing's sarcomas is EWS-Fli1, which occurs in approx. 85 % of cases. The EWS gene is also involved in other translocations to both Ets and non-Ets transcription factor genes, giving rise to Ewing's sarcomas and other cancers [15] [16] [17] [18] . In all cases, the N-terminal domain of EWS is fused, in frame, to a DNA-binding domain of a transcription factor.
EWS fusion proteins are essential for cellular transformation, tumour growth and tumour survival, but how they lead to pathogenesis is not well understood [19] [20] [21] . They are usually suggested to act as aberrant transcription factors causing deregulated expression of numerous genes [13, 15, [22] [23] [24] . However, they may also affect the normal functions of EWS in cells [25] [26] [27] [28] [29] . The mechanisms that might regulate EWS and/or its oncogenic fusions are poorly understood. EWS was reported to be phosphorylated in vitro by PKC (protein kinase C). The site of phosphorylation was not identified, but was suggested to be Ser 266 [30] . Subsequently EWS was shown to be phosphorylated in transfected HEK-293T [human embryonic kidney cells expressing the large T-antigen of SV40 (simian virus 40)] cells and phosphorylation was suppressed by bisindoylmaleimide, a compound which inhibits PKC but also many other protein kinases. The mutation of Ser 266 to alanine suppressed phosphorylation and binding to DNA and reduced the transcriptional activity of the EWS-Fli1 fusion protein by 40 % [31] . An oncogenic protein in which EWS is fused to the WT1 (Wilm's tumour protein 1) was found to be phosphorylated on serine and tyrosine in cells and to be phosphorylated in vitro by the protein tyrosine kinases v-Src and Abbreviations used: ATM, ataxia telangiectasia mutated; ATR, ataxia telangiectasia and Rad3 related; CRE, cAMP-response element; EGF, epidermal growth factor; DAZAP1, DAZ (deleted in azoospermia)-associated protein 1; ERK, extracellular signal-regulated kinase; Ets, E26 transformation-specific; EWS, Ewing's sarcoma protein; FLi1, Friend leukaemia virus integration 1; GST, glutathione transferase; HEK-293 cell, human embryonic kidney cell; HU, hydroxyurea; JNK, c-Jun N-terminal kinase; MALDI-TOF/TOF, matrix-assisted laser-desorption ionization-tandem time-of-flight; MAPK, mitogenactivated protein kinase; MEF, mouse embryonic fibroblast; MEKK, MEK (MAPK/ERK kinase) kinase; MKK, MAPK kinase; MAP3K, MKK kinase; MMS, methyl methanesulphonate; PKC, protein kinase C; siRNA, small interfering RNA; TAK1, TGFβ (transforming growth factor β)-activated kinase-1; TAB1, TAK1-binding protein 1; WT1, Wilm's tumour protein 1.
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c-Abl [32, 33] . Tyrosine phosphorylaton of EWS-WT1 inhibited its binding to DNA and its self-association.
Here we report that EWS and EWS-Fli1 become phosphorylated at Thr 79 in the N-terminal domain in response to mitogens or DNA damage. Mitogen-induced phosphorylation of EWS and EWS-Fli1 was weak and catalysed by ERK1 (extracellular signal-regulated kinase 1) and ERK2. In contrast, DNA damagetriggered phosphorylation of this site was much stronger. The MAPKs (mitogen-activated protein kinases) JNK1 (c-Jun N-terminal kinase 1) and JNK2 contributed to the MMS (methyl methanesulphonate)-induced phosphorylation of EWS, but the p38α/p38β MAPKs were the major kinases phosphorylating EWS-Fli1.
MATERIALS AND METHODS

Materials
Ro 318220 and SB 203580 were purchased from Calbiochem (Nottingham, U.K.) and U0126 from Promega (Southampton, U.K.). PD 184352, BIRB 0796 and Ku 55933 were synthesized by Natalia Shpiro (College of Life Sciences, University of Dundee, U.K.). MMS, HU (hydroxyurea), CPT (camptothecin) and PMA were from Sigma Chemical Co., whereas EGF (epidermal growth factor) was from Invitrogen. Peptides were synthesized by Dr Graham Bloomberg (Department of Biochemistry, University of Bristol, U.K.). SK-ES-1 and RD-ES cell lines, derived from Ewing's sarcoma patients, expressing EWS-Fli1 were obtained from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH; Braunschweig, Germany) and HCT116 human colon carcinoma cells were purchased from the A.T.C.C. MEFs (mouse embryonic fibroblasts) from wild-type and JNK1/JNK2-deficient mice were generated as described in [34] , and ATR flox/− cells were provided by Dr Stephen Elledge (Center for Genetics and Genomics, Harvard Medical School, Boston, MA, U.S.A.).
DNA constructs
EWS was amplified from IMAGE EST (expressed sequence tag) 3449145 using oligonucleotides MP1264 and MP1265 with KOD Hotstart Polymerase (Novagen). The resulting band was cloned into pCR2.1 (Invitrogen), sequenced and then subcloned into the EcoR1/Sal1 sites of pGEX6P1 to form pGEX6P1 EWS. The EWS[T79A] mutant was created using the QuikChange sitedirected mutagenesis kit (Stratagene) with oligonucleotides MP1346 and MP1347. Oligonucleotides used were: MP-1264, GCGAATTCGCGTCCACGGATTACAGTACCTATAG; MP1265, GCGTCGACCTAGTAGGGCCGATCTCTGCGC; MP1346, CCCACTGGTTATACTGCTCCAACTGCCCCCCAG; and MP1347, CTGGGGGGCAGTTGGAGCAGTATAACCAG-TGGG.
Protein preparation
pGEX6P-1 EWS and pGEX6P-1 EWS[T79A] were transformed into the Escherichia coli strain BL21 pLys. The expression was induced with 10 μM IPTG (isopropyl β-D-thiogalactoside) for 16 h at 26
• C, the cells were lysed and GST (glutathione transferase)-fusion proteins were purified by affinity chromatography on glutathione-Sepharose. Activated GST-ERK2, GST-JNK1α1 and GST-p38α MAPK were expressed in E. coli, purified and activated as described in [35] .
Antibodies
An antibody that recognizes phosphorylated and non-phosphorylated forms of EWS equally well was raised in sheep by injection with GST-tagged EWS. The antibody was purified by successive chromatographies on GST-Sepharose and GST-EWS-Sepharose and used in the initial studies (see Results, Figures 1 and 2 ). All subsequent experiments with EWS used a different antibody raised against the C-terminal portion of EWS, BL1085/BET-A300-418A from Axxora (Bingham, Nottinghamshire, U.K.). An anti-Fli1 antibody (C-19, sc-356) from Santa Cruz (Autogen Bioclear, Calne, Wiltshire, U.K.), was used to immunoprecipitate EWS-Fli1. To detect EWS-Fli1 by immunoblotting, an antibody raised against the N-terminal portion of EWS, BL1083/BET-A300-417A, was purchased from Axxora. The phosphopeptide TGYTT*PTAPQ (where T* is phosphothreonine), corresponding to residues 75-84 of human EWS, was coupled separately to BSA and keyholelimpet haemocyanin, mixed and injected into a sheep. The antisera were affinity-purified on a phosphopeptide-antigenSepharose column and used at 3.0 μg/ml for immunoblotting of the immunoprecipitated human protein. Similarly, the phosphopeptide TGYST*PTAPQ, corresponding to residues 75-84 of murine EWS, was used to raise the antibody that recognizes the phosphorylated murine protein and was used at 3.5 μg/ml for immunoblotting. Both phospho-specific antibodies were used in the presence of the appropriate dephosphorylated peptide antigen (10 μg/ml) to neutralize any antibodies that recognised unphosphorylated EWS. The antibodies that recognise c-Jun phosphorylated at Thr 91 [36] and TAB1 {TAK1 [TGFβ (transforming growth factor β)-activated kinase-1]-binding protein} phosphorylated at Ser 423 [37] have been described. Antibodies that recognise the phosphorylated Thr-Glu-Tyr motifs of ERK1 and ERK2, the phosphorylated Thr-Gly-Tyr motif of p38 MAPKs, Chk1 phosphorylated at Ser 345 , and Chk2 phosphorylated at Thr 68 were purchased from Cell Signalling Technologies (Hitchin, U.K.), and the anti-ATR (ataxia telangiectasia and Rad3 related) antibody was from Santa Cruz (Santa Cruz, CA, U.S.A.). The antibody that recognizes the phosphorylated Thr-Pro-Tyr motif of JNKs was from Biosource (Invitrogen, Paisley, U.K.). Rabbit anti-sheep IgG, goat antirabbit IgG and rabbit anti-mouse IgG peroxidase-conjugated antibodies were from Perbio Science (Tattenhall, U.K.).
Cell culture and infection
All cell lines were maintained in a 95 % air/5 % CO 2 atmosphere at 37
• C and cultured according to instructions provided by the supplier. ATR flox/− cells were infected with adenovirus-expressing CRE (cAMP-response element) recombinase, the medium was changed after 48 h, and cells were treated and lysed 72 h postinfection.
Cell stimulation and cell lysis
Unless indicated otherwise, cells were starved for 16 h in culture medium supplemented with 1 % (v/v) penicillin/streptomycin, then stimulated with 2 mM MMS, 2 μg/ml of CPT or 2 mM HU. For ionizing (γ )-radiation, cells were exposed to a 137 Cs source at 10 Gy, and UV radiation was administered with a 254 nm (UV-C) using a Spectrolinker (Spectronics Corp.) at 50 J/m 2 . All treatments were followed by incubation at 37
• C under 5 % CO 2 for the times indicated in the Figure legends. Where required, cells were incubated for 1 h with or without 2 μM PD 184 352, 10 μM U0126, 5 μM Ro 318 220, 3 μM SB 203 580, 0.1, 1 or 10 μM BIRB 0796 or 10 μM KU55933 prior to stimulation. All cells used in the present study were lysed as described previously [38] , lysates were centrifuged at 13 000 g for 10 min at 4
• C, the supernatants (termed cell extracts) were removed, frozen in aliquots in liquid nitrogen and stored at − 20
• C until use.
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Table 1 Tryptic peptides from EWS identified by MALDI-TOF/TOF (matrix-assisted laser-desorption ionization-tandem time-of-flight) MS
Cell extract (10 mg of protein) was incubated for 2 h at 4 • C with 0.05 ml of Protein G-Sepharose, washed as described in the Materials and methods section, and the captured proteins were denatured in SDS, subjected to SDS/PAGE and stained with colloidal Coomassie Blue. The most slowly migrating band recognized by the anti-phospho c-Jun Thr 91 antibody was excised, alkylated with iodoacetamide and digested with trypsin. The resultant peptides were analysed by MALDI-TOF/TOF MS on an Applied Biosystems 4700 Proteomics Analyser. The IPI (International Protein Index) human database was searched using the Mascot search algorithm and scores greater than 60 were considered to be significant (P > 0.05) [52] . 
Figure 1 Identification of proteins phosphorylated in response to EGF in HEK-293 cells
The cells were incubated for 1 h with (+) or without (−) 2 μM PD 184352 or 10 μM U0126, then stimulated for 10 min with EGF (100 ng/ml) and lysed. Cell extract (1 mg of protein) was incubated for 2 h at 4 • C with 0.01 ml of Protein G-Sepharose. After brief centrifugation, the beads were washed once with cell lysis buffer plus 0.5 M NaCl and twice with cell lysis buffer. Bound proteins were released by denaturation in SDS, subjected to SDS/PAGE, transferred to a nitrocellulose membrane, and immunoblotted with an antibody that recognizes c-Jun phosphorylated at Thr 91 . Arrows show the positions of EWS and DAZAP1.
Protein concentrations were determined according to the method of Bradford [39] .
Immunoprecipitation of proteins from cell extracts
Extracts prepared from HEK-293, HCT116, ATR flox/− cell extracts (3 mg lysate protein) and MEFs (10 mg of lysate protein) were immunoprecipitated with an anti-EWS antibody coupled noncovalently to Protein G-Sepharose. Routinely, 0.5 μg of antibody was used to immunoprecipitate EWS from 1 mg of extract protein.
Extracts from SK-ES-1 and RD-ES cells (3 mg of lysate protein) were immunoprecipitated with 9 μg of anti-Fli1 antibody coupled non-covalently to Protein G-Sepharose. Immunoprecipitation was carried out for 2 h at 4
• C with continuous agitation. Following centrifugation for 2 min at 5000 g, the supernatants were discarded and the pellet washed once in lysis buffer containing 0.5 M NaCl, then twice in lysis buffer alone. Samples were denatured in SDS, subjected to SDS/PAGE, transferred to PVDF membranes and immunoblotted using the enhanced chemiluminescence detection system.
Phosphorylation of EWS by ERK2, JNK1α1 and p38α MAPK in vitro
Bacterially expressed GST-EWS and GST-EWS[T79A] were incubated for 30 min at 30
• C alone or with 2 units/ml of either ERK2, JNK1α1 or p38α MAPK in the presence of 0.1 mM ATP and 10 mM MgCl 2 . Reactions were terminated with SDS, then samples were subjected to SDS/PAGE and immunoblotted. Alternatively, reaction aliquots were spotted on to nitrocellulose membranes and analysed by immunoblotting.
RESULTS
Identification of EWS as a substrate for ERK1/ERK2 in EGF-stimulated HEK-293 cells
We have previously identified two proteins, DAZAP1 [DAZ (deleted in azoospermia)-associated protein 1] and hnRNP K (heterogenous ribonucleoprotein K), that become phosphorylated by the MAPKs ERK1 and ERK2 in LPS (lipopolysaccharide)-stimulated RAW 264.7 macrophages [40] . The phosphorylation of these proteins was detected because, similar to many RNAbinding proteins, they were retained on Protein G-Sepharose and, in stimulated cells, cross-reacted with a phospho-specific antibody that recognises c-Jun phosphorylated at Thr 91 [36] . Using the same approach, we detected two proteins in EGFstimulated HEK-293 cells that were recognized by a phosphospecific antibody raised against a peptide corresponding to the sequence surrounding Thr 91 of c-Jun. The phosphorylation of both proteins was prevented by prior incubation of the cells with either of two structurally unrelated inhibitors of MKK1/MKK2, PD 184352 and U0126 ( Figure 1A ). Since PD 184352 does not affect MKK5 (the upstream activator of ERK5) at the concentration used (2 μM), this indicated that both proteins were phosphorylated by a protein kinase lying downstream of MKK1/MKK2, presumably their substrates ERK1 and ERK2 or a protein kinase activated by ERK1/ERK2. The two proteins were purified and identified by tryptic mass fingerprinting. The faster migrating species was DAZAP1 (results not shown), whereas the more slowly migrating protein was identified as EWS (Table 1 ). (B and C) Cells were incubated for 1h with (+) or without (−) 2 μM PD 184352 or 10 μM U0126, then stimulated for 10 min with 100 ng/ml EGF (B) or 100 ng/ml PMA (C) and lysed. Cell extract (60 μg protein) was denatured, subjected to SDS/PAGE and immunoblotted with the antibodies used in (A). Note that pEWS runs just above a non-specific band in (C).
EWS is phosphorylated at Thr 79 by ERK2 in vitro and by ERK1/ERK2 in cells
The amino acid residue immediately C-terminal to Thr 91 of cJun is a proline and the residue in DAZAP-1 recognized by the anti-phospho-Thr 91 antibody also lies in a phosphothreonylproline sequence. This suggested that EWS might also be phosphorylated at a Thr-Pro sequence, presumably by ERK1/ERK2, which invariably phosphorylate Ser/Thr-Pro sequences. In EWS, only Thr 79 lies in a Thr-Pro sequence. Therefore, to test whether this was the site of phosphorylation, bacterially expressed wildtype GST-EWS and GST-EWS[T79A] were incubated with ERK2 and Mg-ATP in vitro. Following phosphorylation, only the wild-type protein was recognized by the anti-phospho-Thr 91 antibody ( Figure 2A, top panel) , demonstrating that Thr 79 is phosphorylated by ERK2 in vitro. We also raised an antibody capable of recognizing EWS only when phosphorylated at Thr 79 . As expected, this antibody also recognized wild-type GST-EWS, but not GST-EWS[T79A], following phosphorylation by ERK2 (Figure 2A, middle panel) . This antibody also recognized EWS in HEK-293 cells stimulated with EGF ( Figure 2B ) or PMA ( Figure 2C) Figure 3A) . Phosphorylation peaked after 2 h and declined thereafter, and correlated with phosphorylation of the activation loops of two other MAPK subfamilies, namely p38α/p38β MAPKs and JNK1/JNK2. The DNA damage response pathway was assessed by monitoring the phosphorylation of the protein kinases Chk2 and Chk1, which are phosphorylated and activated by the protein kinases ATM (ataxia telangiectasia mutated) and ATR respectively. These studies revealed that the DNA damage response was activated prior to the phosphorylation of p38 MAPK, JNK and EWS in these cells ( Figure 3A) .
Interestingly, the phosphorylation of EWS at Thr 79 in response to MMS was much stronger than that induced by PMA, whereas PMA was a much stronger activator of ERK1/ERK2 than MMS and did not activate Chk2 ( Figure 3B ). We also exposed the cells to other types of DNA damage. UV radiation triggered the phosphorylation of EWS at Thr 79 , although to a lesser extent than MMS, whereas CPT, an inhibitor of topoisomerase I, HU, an inhibitor of ribonucleotide reductase, and ionizing γ -radiation induced only a weak phosphorylation of this site ( Figure 3C ). All five agonists activated the DNA damage response pathways, JNK and p38 MAPK, but to different extents. Since MMS induced the strongest phosphorylation of EWS, we used this agonist to analyse the signalling pathways that mediate the phosphorylation of Thr 79 .
Signalling pathways that trigger the phosphorylation of EWS at Thr 79
In contrast to the PMA-induced phosphorylation of Thr 79 , which was prevented by inhibition of MKK1/MKK2, the MMS-induced phosphorylation of Thr 79 was not, implying that ERK1/ERK2 were not rate limiting for the MMS-stimulated phosphorylation of EWS at this site ( Figure 4A ). Similar to ERK1/ERK2, ERK8 activity was also not rate limiting for the MMS-induced phosphorylation of Thr 79 , since Ro 318220 did not affect it at concentrations that prevent ERK8 activation (results not shown [38] ).
Since MMS induced activation of both JNK and p38 MAPK correlated with the phosphorylation of EWS at Thr 79 ( Figure 3A) , we next investigated if these kinases were capable of phosphorylating EWS in vitro. Incubation of bacterially expressed wild-type GST-EWS, but not GST-EWS[T79A], with either JNK1α1 or p38α MAPK and MgATP led to its phosphorylation at Thr 79 in vitro ( Figure 4B ). We then examined whether p38α MAPK phosphorylated EWS in response to MMS in HEK-293 cells. However, neither SB 203580 nor BIRB 0796, two structurally unrelated inhibitors of p38α/p38β MAPKs, affected EWS phosphorylation at Thr 79 at concentrations where both inhibitors abrogated the phosphorylation of TAB1 at Ser 423 ( Figure 4C ), a site targeted by p38α MAPK in cells [37] .
Figure 3 Effect of MMS on EWS phosphorylation in HEK-293 cells
(A) Cells were treated with 2 mM MMS and lysed at the times indicated. EWS was immunoprecipitated (IP) from the cell extracts using an anti-EWS antibody coupled to Protein G-Sepharose as described in the Materials and methods section. Captured proteins were denatured, subjected to SDS/PAGE and immunoblotted with antibodies that recognize human EWS phosphorylated at Thr 79 [pEWS (Thr79)] or an anti-EWS antibody (Bethyl, C-terminal) that recognizes the phosphorylated and unphosphorylated forms of EWS equally well. In addition, cell extracts (60 μg of protein) were denatured, resolved by SDS/PAGE, transferred to a PVDF membrane, and immunoblotted with antibodies that recognise Chk1 phosphorylated at 
JNK1/JNK2 contribute to EWS phosphorylation at Thr 79
Although BIRB 0796 inhibits p38α/p38β MAPKs specifically when included in the cell culture medium at 0.1 μM, it blocks p38γ and p38δ MAPKs completely when included in the culture medium at 1 μM, whereas at 10 μM, BIRB 0796 also suppresses the activation and activity of JNKs [41] . HEK-293 cells were therefore incubated with a range of concentrations of BIRB 0796 prior to stimulation with MMS. These experiments showed that BIRB 0796 had little effect on the MMS-stimulated phosphorylation of Thr 79 up to and including 1 μM, but suppressed it completely at 10 μM ( Figure 5A ). This suggested that one or more JNK isoforms might mediate MMS-induced EWS phosphorylation.
In order to obtain further information as to whether JNK isoforms were important for the phosphorylation of EWS, we used MEFs that do not express JNK1 or JNK2, the only two JNK isoforms expressed in these cells. The amino acid sequence immediately surrounding Thr 79 of murine EWS shows one difference from human EWS and the phospho-specific antibody raised against the human sequence did not recognize mouse EWS. For these reasons, we raised a separate phospho-specific antibody directed against the murine sequence. Using this antibody, we observed that MMS induced a weak phosphorylation of EWS at Thr 79 that was similar in both wild-type MEFs and JNK-deficient MEFs, indicating phosphorylation was not catalysed by JNK1/ JNK2 ( Figure 5B ). Phosphorylation was also unaffected by PD 184352, excluding the involvement of ERK1/ERK2 (results not shown). However, if the cells were first treated with SB 203580 to inhibit p38α/p38β MAPKs, MMS now induced a much stronger phosphorylation of EWS at Thr 79 in the wildtype cells, but not in the JNK-deficient cells. Moreover, in the presence of SB 203580, MMS induced a stronger activation of JNK in the wild-type cells ( Figure 5B ). These observations demonstrated that p38α/p38β MAPKs exert a negative feedback control on the MMS-induced activation of JNK in wild-type MEFs, explaining why JNKs become strongly activated when p38α/p38β MAPK activity is blocked. The failure of MMS to induce phosphorylation of EWS in SB 203580-treated, JNKdeficient cells implied that JNKs are responsible for the strong MMS-induced phosphorylation of EWS at Thr 79 in SB 203580-treated wild-type cells. These results, which indicate that at least two protein kinases are involved in mediating the MMS-induced phosphorylation of EWS in MEFs, are considered further in the Discussion section.
Involvement of the protein kinases ATM and ATR in the MMS-induced phosphorylation of EWS at Thr 79
The protein kinases ATM and ATR are the components of the signalling pathways that become activated in cells upon damage to DNA. We therefore addressed whether these two kinases are required for the phosphorylation of EWS in response to MMS. To investigate if the ATM protein kinase was required, we used Ku 55933, a relatively specific inhibitor of ATM that does not inhibit ATR [42] . These experiments showed that Ku 55933 caused a significant inhibition of the MMS-induced phosphorylation of EWS at Thr 79 and a greater but still incomplete inhibition of the phosphorylation of Chk2 ( Figure 6A ).
To investigate if ATR was required for MMS-induced phosphorylation of EWS, we exploited HCT116 cells in which one allele of ATR had been disrupted, the other allele being flanked by flox recombination sequences [43] . Upon viral transduction of the CRE recombinase, the remaining ATR allele is removed and the cells effectively become ATR deficient, as shown by the almost complete suppression of the activation of Chk1 ( Figure 6B ). We found that the MMS-induced phosphorylation of EWS was reduced in ATR-deficient cells ( Figure 6B ). When the ATRdeficient cells were pre-incubated with Ku 55933 a slightly greater reduction in MMS-induced Thr 79 phosphorylation was observed. Taken together, these results suggest a role for ATM/ATR in the MMS-stimulated phosphorylation of Thr 79 in HCT116 cells. However, it should be noted that in Ku 55933-treated ATRdeficient HCT116 cells, the MMS-induced activation of JNK was only reduced slightly, despite the complete inhibition of Chk1 and Chk2 activity. These results are considered further in the Discussion section.
Phosphorylation of EWS-Fli1 at Thr 79 in Ewing's sarcoma cells
Having established that wild-type EWS becomes phosphorylated at Thr 79 in response to mitogens or DNA damage, we next investigated whether the oncogenic EWS fusion proteins were also phosphorylated at this site, since they all encompass the N-terminal region of EWS fused in-frame to the DNA-binding domain of an Ets transcription factor. We used two cell lines derived from Ewing's sarcoma patients, SK-ES-1 and RD-ES, both of which express the EWS-Fli1 fusion. We first examined if the fusion protein became phosphorylated at Thr 79 in response to agonists that trigger phosphorylation of the wild-type protein. SK-ES-1 cells were stimulated with PMA to activate the classical MAPK pathway or exposed to MMS to induce DNA damage (Figure 7A) . The EWS-Fli1 fusion protein became phosphorylated in response to both agonists, MMS inducing a far stronger phosphorylation, similar to that observed with wild-type EWS.
MMS-induced phosphorylation of EWS-Fli1 at Thr 79 is strongly suppressed by inhibitors of p38α/p38β MAPKs
To investigate whether the protein kinase(s) responsible for phosphorylating EWS-Fli1 in response to MMS was the same as that (those) phosphorylating EWS itself, we initially used inhibitors of p38α/p38β MAPKs. Surprisingly, and in contrast to the lack of effect of these inhibitors on the phosphorylation of EWS, the MMS-induced phosphorylation of EWS-Fli1 was strongly reduced by either SB 203580 or BIRB 0796 in SK-ES-1 ( Figure 7B ) and RD-ES cells ( Figure 7C ). These results indicated that p38α/p38β MAPKs are major protein kinases phosphorylating EWS-Fli1 in response to MMS. Both SK-ES-1 and RD-ES cells express the wild-type EWS protein in addition to EWS-Fli1. As reported previously for other Ewing's sarcoma cell lines [44] , EWS co-immunoprecipitated with EWS-Fli1 in both cell lines, indicating that the N-terminal domain of EWS is capable of homodimerization. Consistent with the observations made in HEK-293 cells, the MMS-induced phosphorylation of the EWS that immunoprecipitated with EWSFli1 was unaffected by the inhibition of p38α/p38β MAPKs.
Interestingly, although similar amounts of EWS and EWS-Fli1 were immunoprecipitated with anti-Fli1 antibody in SK-ES-1 cells, the MMS-induced phosphorylation of EWS-Fli1 was much stronger than that of EWS ( Figure 7B ). This difference was even more striking in RD-ES cells, where no MMSinduced phosphorylation of the EWS that immunoprecipitated with EWS-Fli1 was observed ( Figure 7C ). These results suggest that either EWS is a poorer substrate for EWS kinases when bound to EWS-Fli1, or that the phosphorylated form of EWS interacts less strongly with EWS-Fli1.
DISCUSSION
In the present study we have identified EWS as a physiological substrate for several MAPKs in mammalian cells. EWS became phosphorylated at Thr 79 when HEK-293 cells were stimulated with EGF or PMA. This residue was phosphorylated by ERK2 in vitro and the phosphorylation of EWS in HEK-293 cells was prevented by inhibition of MKK1/MKK2, the upstream activators of ERK1/ERK2. This implies that ERK1/ERK2 mediate the mitogen-induced phosphorylation of EWS. However, a much more striking phosphorylation of EWS at Thr 79 was observed when HEK-293 cells were exposed to DNA-damaging agents, especially MMS, which was unaffected by the inhibition of MKK1/MKK2, p38α, p38β, p38γ and p38δ MAPKs or ERK8. The identity of the protein kinase(s) that mediates MMS-induced phosphorylation of EWS in HEK-293 cells is not fully resolved. The phosphorylation of EWS was prevented by high (10 μM) concentrations of BIRB 0796, which is known to prevent the activation and activity of JNK isoforms [41] , suggesting that these MAPKs may phosphorylate EWS in response to MMS in HEK-293 cells. However, at these high concentrations of BIRB 0796, other protein kinases are also inhibited [45] .
In contrast, the weak MMS-induced phosphorylation of EWS observed in MEFs was not only unaffected by PD 184352, but also unimpaired in JNK-deficient cells ( Figure 5B), and also appeared to be unaffected by high (10 μM) concentrations of BIRB0796 in wild-type MEFs (results not shown). These experiments therefore appear to exclude a role for JNK isoforms in the weak phosphorylation of EWS induced by MMS in MEFs. The much stronger MMS-stimulated phosphorylation of EWS in human HEK-293 cells (Figures 4 and 5A) , human HCT116 cells ( Figure 6B ) and human HeLa cells (results not shown) may therefore represent a species or cell-specific difference.
However, in wild-type MEFs (but not in HEK-293 cells) prior incubation of the cells with inhibitors of p38α/p38β MAPKs greatly potentiated the MMS-stimulated activation of JNK and the phosphorylation of EWS. In contrast, the p38 MAPK inhibitors had no effect on the phosphorylation of EWS in JNK-deficient MEFs. These results imply that p38α/p38β MAPKs partially suppress the activation of JNKs in MEFs by inhibiting an upstream activator of the pathway. This could be one or more MAP3Ks (MKK kinases), since p38α/β MAPKs are known to downregulate TAK1 [37] and MLK3 (mixed lineage kinase 3) [46] ; these MAP3Ks activate JNKs in response to several stimuli. Why JNKs only phosphorylate EWS in MEFs in the presence of p38α/p38β MAPK inhibitors is unclear, but their failure to colocalize in the absence of these inhibitors may be one explanation. In summary, our results indicate that at least two types of protein kinase phosphorylate EWS, one of which may be a JNK isoform.
Interestingly, the inhibition of ATM and/or depletion of ATR, which are key components of the classical DNA damage response pathway, partially suppressed the MMS-induced phosphorylation of EWS at Thr 79 in HCT116 cells. However, only a minor decrease in JNK activation was observed even when both ATM and ATR were completely inhibited or depleted. These results indicate that ATM/ATR are not rate limiting in the MMS-induced activation of JNK but that they might lie upstream of another protein kinase that phosphorylates EWS in HCT116 cells. The signalling pathway(s) that mediate(s) the MMS-induced activation of JNK remains to be identified. The TAO (thousand and one) isoforms are activated by DNA damage, but as these MAP3Ks were reported to require ATM for activation [47] , their involvement can probably be excluded. Other candidates include MEKK1 [MEK (MAPK/ERK kinase) kinase] [48, 49] and MEKK4 [50] , whose activation by DNA damage has been reported. We have also found that MMS induces the activation of TAK1 (M. Windheim, I. Klevernic and P. Cohen, unpublished work).
The molecular actions of EWS in cells are unknown. However, EWS-null mice display premature signs of aging compared to wild-type animals and MEFs derived from the knock-out mice stop proliferating in culture after a few passages and undergo senescence. Of particular relevance to the present study, both EWS-null animals, and MEFs derived from them, displayed hypersensitivity to DNA damage [4] , and siRNA 'knock-down' of EWS in Hela cells caused mitotic defects and apoptosis [5] . It would clearly be of interest to know whether the phosphorylation of EWS at Thr 79 enhances or suppresses these phenotypes. The chemotherapeutic agent fenretinide was reported to trigger the apoptosis of cell lines derived from Ewing's sarcoma patients. This was suppressed by pharmacological inhibition of p38α/p38β MAPK [51] and fenretinide-mediated activation of p38α/p38β MAPK was attenuated when the expression of EWSFli1 was decreased using siRNA. These studies linked EWS-Fli1 with the fenretinide-induced activation of p38α/p38β MAPK. Here we have reported a quite different connection between p38α/p38β MAPK and EWS-Fli1. In contrast to EWS itself, we found that the MMS-induced phosphorylation of EWS-Fli1 was largely mediated by p38α/p38β MAPKs. It will be important to investigate how the p38α/p38β-stimulated phosphorylation of EWS-fusion proteins affects their ability to transactivate and their oncogenic potential.
